All PlansAdministrativeMedium impact
Voluntary nationwide recall: Duloxetine (Towa – October)
UPMC Health Plan·Pharmacy, Psychiatry, Pain Management +1 more·Pharmacy
Effective date
Oct 23, 2024
We identified it
Aug 7, 2026
Summary
Towa Pharmaceutical is recalling lot 220128 of Duloxetine Delayed-Release Capsules, USP, 20 mg due to impurity N-nitroso-duloxetine. The FDA advises patients taking the affected lot to stop use and return or discard the medication. Billing teams should be prepared to address potential claim adjustments, reversals, or patient refunds if affected prescriptions were recently processed.
Action Required
By November 26, 2024: Billing team should identify and flag any claims submitted for Duloxetine Delayed-Release Capsules, USP, 20 mg (lot 220128) from affected date ranges. Coordinate with pharmacy and providers to determine if patients received the recalled lot. Be prepared to process refunds, reversals, or adjustments to claims if the recalled medication was dispensed. Communicate with affected patients through standard patient account channels regarding potential billing corrections. Document all actions taken in billing system for audit purposes.